Skip to content
Tazemetostat Withdrawl and RECITE episode artwork

Mar 19, 2026 14 min

Tazemetostat Withdrawl and RECITE

from OncoPharm Hosted by John Bossaer

Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it does, but does that make a difference? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Tazemetostat Withdrawl and RECITE

0:00 14:47

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OncoPharm?

This episode is 14 minutes long.

When was this OncoPharm episode published?

This episode was published on March 19, 2026.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.